
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
The Center for Drug Evaluation and Research is adopting new approaches to how it oversees the development and approval of new drugs and how it ensures the safe use of prescription drugs by the public.
over 25 years ago
Report on the Industry Blend Uniformity Practices Surveyover 25 years ago
Interphex Presents a Wide Array of Packaging Innovations




